These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 19247086)

  • 21. [Chemoradiotherapy followed by surgery in treatment of locally advanced esophageal carcinoma: a phase II trial].
    Fu JH; Rong TH; Li XD; Hu Y; Ou W; Hu YH; Li Q
    Ai Zheng; 2004 Nov; 23(11 Suppl):1473-6. PubMed ID: 15566661
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nodal metastasis from locally advanced esophageal cancer: how neoadjuvant therapy modifies their frequency and distribution.
    Castoro C; Scarpa M; Cagol M; Ruol A; Cavallin F; Alfieri R; Zanchettin G; Rugge M; Ancona E
    Ann Surg Oncol; 2011 Dec; 18(13):3743-54. PubMed ID: 21556952
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Different recurrence pattern after neoadjuvant chemoradiotherapy compared to surgery alone in esophageal cancer patients.
    Smit JK; Güler S; Beukema JC; Mul VE; Burgerhof JG; Hospers GA; Plukker JT
    Ann Surg Oncol; 2013 Nov; 20(12):4008-15. PubMed ID: 23838922
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Does Barrett's esophagus respond to chemoradiation therapy for adenocarcinoma of the esophagus?
    Barthel JS; Kucera ST; Lin JL; Hoffe SE; Strosberg JR; Ahmed I; Dilling TJ; Stevens CW
    Gastrointest Endosc; 2010 Feb; 71(2):235-40. PubMed ID: 20003971
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Morbidity and mortality are not increased after induction chemoradiotherapy followed by esophagectomy in patients with esophageal cancer.
    Berger AC; Scott WJ; Freedman G; Konski A; Weiner L; Cheng JD; Goldberg M
    Semin Oncol; 2005 Dec; 32(6 Suppl 9):S16-20. PubMed ID: 16399424
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Radiation dose does not influence anastomotic complications in patients with esophageal cancer treated with neoadjuvant chemoradiation and transhiatal esophagectomy.
    Koëter M; van der Sangen MJ; Hurkmans CW; Luyer MD; Rutten HJ; Nieuwenhuijzen GA
    Radiat Oncol; 2015 Mar; 10():59. PubMed ID: 25884226
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adenocarcinoma of the esophagus and esophagogastric junction in patients older than 70 years: results of neoadjuvant radiochemotherapy followed by transthoracic esophagectomy.
    Camerlo A; D'Journo XB; Ouattara M; Trousse D; Doddoli C; Thomas PA
    J Visc Surg; 2012 Jun; 149(3):e203-10. PubMed ID: 22633088
    [TBL] [Abstract][Full Text] [Related]  

  • 28. American Joint Committee on Cancer staging system does not accurately predict survival in patients receiving multimodality therapy for esophageal adenocarcinoma.
    Rizk NP; Venkatraman E; Bains MS; Park B; Flores R; Tang L; Ilson DH; Minsky BD; Rusch VW;
    J Clin Oncol; 2007 Feb; 25(5):507-12. PubMed ID: 17290058
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Complete pathologic response after neoadjuvant chemoradiotherapy for esophageal cancer is associated with enhanced survival.
    Donahue JM; Nichols FC; Li Z; Schomas DA; Allen MS; Cassivi SD; Jatoi A; Miller RC; Wigle DA; Shen KR; Deschamps C
    Ann Thorac Surg; 2009 Feb; 87(2):392-8; discussion 398-9. PubMed ID: 19161745
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Induction chemoradiotherapy and surgery for esophageal cancer: survival benefit with downstaging.
    Taylor MD; LaPar DJ; Davis JP; Isbell JM; Kozower BD; Lau CL; Jones DR
    Ann Thorac Surg; 2013 Jul; 96(1):225-30: discussion 230-1. PubMed ID: 23618518
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The impact of neoadjuvant chemoradiotherapy on perioperative outcomes, tumor pathology, and survival in clinical stage II and III esophageal cancer.
    Markar SR; Bodnar A; Rosales J; Song G; Low DE
    Ann Surg Oncol; 2013 Nov; 20(12):3935-41. PubMed ID: 23892525
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Factors affecting postoperative course and survival after en bloc resection for esophageal carcinoma.
    Mariette C; Taillier G; Van Seuningen I; Triboulet JP
    Ann Thorac Surg; 2004 Oct; 78(4):1177-83. PubMed ID: 15464466
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery.
    Jin J; Liao Z; Zhang Z; Ajani J; Swisher S; Chang JY; Jeter M; Guerrero T; Stevens CW; Vaporciyan A; Putnam J; Walsh G; Smythe R; Roth J; Yao J; Allen P; Cox JD; Komaki R
    Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):427-36. PubMed ID: 15380576
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Importance of residual primary cancer after induction therapy for esophageal adenocarcinoma.
    Raja S; Rice TW; Ehrlinger J; Goldblum JR; Rybicki LA; Murthy SC; Adelstein D; Videtic G; McNamara MP; Blackstone EH
    J Thorac Cardiovasc Surg; 2016 Sep; 152(3):756-761.e5. PubMed ID: 27530636
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase II study of chemoradiotherapy with 5-fluorouracil and cisplatin for Stage II-III esophageal squamous cell carcinoma: JCOG trial (JCOG 9906).
    Kato K; Muro K; Minashi K; Ohtsu A; Ishikura S; Boku N; Takiuchi H; Komatsu Y; Miyata Y; Fukuda H;
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):684-90. PubMed ID: 20932658
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multimodal treatment strategy for clinical T3 thoracic esophageal cancer.
    Saeki H; Morita M; Tsuda Y; Hidaka G; Kasagi Y; Kawano H; Otsu H; Ando K; Kimura Y; Oki E; Kusumoto T; Maehara Y
    Ann Surg Oncol; 2013 Dec; 20(13):4267-73. PubMed ID: 23943036
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Delaying surgery after neoadjuvant chemoradiotherapy does not significantly influence postoperative morbidity or oncological outcome in patients with oesophageal adenocarcinoma.
    Kathiravetpillai N; Koëter M; van der Sangen MJ; Creemers GJ; Luyer MD; Rutten HJ; Nieuwenhuijzen GA
    Eur J Surg Oncol; 2016 Aug; 42(8):1183-90. PubMed ID: 27134188
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Minimally invasive esophagectomy for stage I and II esophageal cancer.
    Yamamoto S; Kawahara K; Maekawa T; Shiraishi T; Shirakusa T
    Ann Thorac Surg; 2005 Dec; 80(6):2070-5. PubMed ID: 16305846
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Improved outcomes in the management of esophageal cancer with the addition of surgical resection to chemoradiation therapy.
    McKenzie S; Mailey B; Artinyan A; Metchikian M; Shibata S; Kernstine K; Kim J
    Ann Surg Oncol; 2011 Feb; 18(2):551-8. PubMed ID: 20839062
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association of treatment factors with surgical outcomes in tri-modality therapy for esophageal cancer.
    Shaikh T; Thomay A; Ruth K; Cohen SJ; Meyer JE
    J Surg Oncol; 2015 Nov; 112(6):629-33. PubMed ID: 26430952
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.